Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azacitidine + golidocitinib + cyclophosphamide + doxorubicin + vincristine + prednisone
- Development stage
- Phase 2
- Lead developer
- Dizal Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
Azacitidine + golidocitinib + CHOP is an investigational combination regimen being evaluated for the frontline treatment of newly diagnosed peripheral T-cell lymphoma (PTCL). This regimen utilizes a genotype-guided strategy, combining the hypomethylating agent azacitidine (a DNA methyltransferase inhibitor), the selective JAK1 inhibitor golidocitinib, and the standard CHOP chemotherapy backbone (cyclophosphamide, doxorubicin, vincristine, and prednisone). Azacitidine is intended to act as an epigenetic primer, potentially sensitizing lymphoma cells to chemotherapy by inhibiting DNA methylation. Golidocitinib specifically targets the JAK1/STAT signaling pathway, which is frequently dysregulated in T-cell malignancies. The combination is currently being studied in a Phase I/II clinical trial led by Ruijin Hospital to determine the recommended Phase II dose and evaluate efficacy compared to standard CHOP.
- Other names
- Azacitidine plus Golidocitinib with CHOPCHOPX2CHOPX-2CHOPX 2
02
Targets
DNATOP2A (DNA topoisomerase II)DNMT1 (DNA (cytosine-5)-methyltransferase 1)GR (Glucocorticoid receptor)JAK1 (Janus kinase 1)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on azacitidine + golidocitinib + cyclophosphamide + doxorubicin + vincristine + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azacitidine + golidocitinib + cyclophosphamide + doxorubicin + vincristine + prednisone.